Home/Pipeline/REGN5458

REGN5458

Multiple Myeloma

Phase 1/2ActiveN/A

Key Facts

Indication

Multiple Myeloma

Phase

Phase 1/2

Status

Active

Company

Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron is a premier biotechnology company with a mission to translate groundbreaking science into life-changing medicines for patients. Its achievements are anchored by its proprietary VelociSuite® technology platforms, which have enabled the development of a robust commercial portfolio and one of the industry's deepest pipelines. The company's strategy combines sustained internal R&D investment with selective, high-value collaborations, all supported by a fully integrated model from discovery to global commercialization.

View full company profile

Therapeutic Areas

Ophthalmology Cardiovascular & Metabolic Diseases Oncology & Hematology Allergic & Inflammatory Diseases Rare Diseases Infectious Diseases Neuroscience Pain

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
PRG1801 (Anti-BCMA CAR-T)	Pregene Biopharma	Phase 1	Active
CAR-NK Therapy	Pregene Biopharma	Phase 1	Active (recruiting)
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
BCMA CAR-T	Simnova Biotherapeutics	Phase 1	Active
BCMA panCAR (via Orna partnership)	Simnova Biotherapeutics	Preclinical	Active
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active